Assessment of the hepatocyte protective effects of gypenoside and its phosphorylated derivative against DHAV-1 infection on duck embryonic hepatocytes

Table 2 A₅₇₀ values of different treatments when adding drug firstly (n = 6)

GP Concentration (μg/mL)	A ₅₇₀	Hepatocyte protection rate rate (%)	pGP Concentration (μg/mL)	A ₅₇₀	Hepatocyte protection rate rate(%)
100	0.351 ± 0.007^b	48.17	25	0.405 ± 0.007^a	93.55
50	0.298 ± 0.007^c	20.42	12.5	0.306 ± 0.006^b	40.32
25	0.274 ± 0.012^cd	7.85	6.25	0.297 ± 0.008^b	35.48
12.5	0.285 ± 0.007^cd	13.61	3.125	0.276 ± 0.009^c	24.19
6.25	0.279 ± 0.011^cd	10.47	1.5625	0.269 ± 0.006^c	20.43
0(VC)	0.259 ± 0.012^d		0(VC)	0.231 ± 0.007^d
0(CC)	0.450 ± 0.009^a		0(CC)	0.417 ± 0.008^a

^a-dData in same column without same superscript (a–d) differ significantly(p < 0.05)
GP Gypenoside, pGP phosphorylated gypenoside, VC virus control, CC cell control

ISSN: 1746-6148